DoD Lung Cancer, Investigator-Initiated Translational Research Award

The summary for the DoD Lung Cancer, Investigator-Initiated Translational Research Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Lung Cancer, Investigator-Initiated Translational Research Award: The FY20 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:· Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts.· Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission.· Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials.Preliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required.